Skip to content
Review

FDG-PET in Cognitive Impairment and Dementia.

Oct 2026 · PET Clinics · Vol 21 4, pp. 483-497 · 0 citations · 79 references
Medicine

Abstract

Neuroimaging is crucial in early and accurate assessment of diagnosis, prognosis, and therapy optimization in patients with declining cognitive abilities. Imaging modalities now available for clinical indications related to neurodegenerative processes include Computed Tomography (CT), MR imaging, and PET imaging with 6 positron-emitting radiotracers approved at this time by the US Food and Drug Administration. The central focus of this article is the role of FDG-PET in clinical and research applications of patients with cognitive problems, and how the derived information may be effectively integrated with information acquired from other neuroimaging modalities.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.